Scholarlink

<p>Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18–24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56–73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Serena Maria Carli,
  • Paola Mencarini,
  • Maria Angela Vittoria Licata,
  • Maria Musso,
  • Carlotta Cerva,
  • Annelisa Mastrobattista,
  • Pietro Vittozzi,
  • Silvia Mosti,
  • Carla Nisii,
  • Antonio Mazzarelli,
  • Assunta Navarra,
  • Gabriella De Carli,
  • Stefania Ianniello,
  • Fabrizio Palmieri,
  • Gina Gualano

摘要

Treatment of NTM lung disease (NTM-LD) is based on combinations of antimycobacterial drugs. It lasts 12 months if respiratory samples become culture negative, while in refractory cases it can last up to 18–24 months. Therapeutic pathway is complicated by frequent adverse events (AEs). Sometimes, symptomatic therapy is not sufficient to control AEs, making necessary to suspend the drug involved or the entire treatment. This study aims to describe the frequency and type of AEs in patients with NTM-LD and to evaluate their impact on the outcomes of treatment. This is a retrospective observational study. We analysed clinical data, regimen composition, AEs and outcomes of NTM-LD patients followed between January 2016 and June 2023 at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. Out of 131 patients, fifty-eight (44.3%) were men; median age was 66 years (IQR: 56–73). One hundred (76.3%) developed AEs. Total AEs were 229, of which 81 were serious adverse events (SAEs). Cure was obtained in 113 cases (86.3%), therapeutic failure occurred in 10 (7.6%), 6 patients died (4.6%), and 2 (1.5%) were lost-to-follow-up. Despite of AEs, most patients were able to complete treatment with appropriate management and monitoring. AEs affect patient quality of life and treatment adherence. Therefore, it is important to identify factors that can predict and prevent them. Clear and detailed information about drug side effects, with instructions to follow in case of AEs, active monitoring at every contact, flexibility and accessibility to healthcare professionals are key factors for therapy success.